 LONDON, April 21, 2021 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN the Company or Freeline, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases today announced participation in the following virtual investor conferences: 